Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Hui-Rong Qian"'
Autor:
Nicholas R. Powell, Tiebing Liang, Joseph Ipe, Sha Cao, Todd C. Skaar, Zeruesenay Desta, Hui-Rong Qian, Philip J. Ebert, Yu Chen, Melissa K. Thomas, Naga Chalasani
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
This study characterizes expression of pharmacogenes across the histological NAFLD severity spectrum. Here, the authors show the downregulation of CYP2C19 in NAFLD which supports developing personalized medicine approaches for drugs sensitive to meta
Externí odkaz:
https://doaj.org/article/a90be45cc8cb455db34c7afe0b5d1181
Autor:
Steven M. Bray, Jeeyun Lee, Seung Tae Kim, Joon Young Hur, Philip J. Ebert, John N. Calley, Isabella H. Wulur, Thejaswini Gopalappa, Swee Seong Wong, Hui-Rong Qian, Jason C. Ting, Jiangang Liu, Melinda D. Willard, Ruslan D. Novosiadly, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Amit Aggarwal, Hee Cheol Kim, Christoph Reinhard
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Abstract Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in
Externí odkaz:
https://doaj.org/article/f456fa8deb9947ea89d5b6e8de43eb83
Autor:
Hong Wang, Yupeng Li, John W. Ryder, Justin T. Hole, Philip J. Ebert, David C. Airey, Hui-Rong Qian, Benjamin Logsdon, Alice Fisher, Zeshan Ahmed, Tracey K. Murray, Annalisa Cavallini, Suchira Bose, Brian J. Eastwood, David A. Collier, Jeffrey L. Dage, Bradley B. Miller, Kalpana M. Merchant, Michael J. O’Neill, Ronald B. Demattos
Publikováno v:
Molecular Neurodegeneration, Vol 13, Iss 1, Pp 1-19 (2018)
Abstract Background Activation of microglia, the resident immune cells of the central nervous system, is a prominent pathological hallmark of Alzheimer’s disease (AD). However, the gene expression changes underlying microglia activation in response
Externí odkaz:
https://doaj.org/article/96f83b1cdfe5461fbb9ab739a9f3c4f2
Autor:
Sean G. Buchanan, James R. Henry, Robert M. Campbell, Christoph Reinhard, Gregory D. Plowman, David A. Barda, Xiang S. Ye, Hui-Rong Qian, Shaoyou Chu, Thompson Doman, Matthew Z. Dieter, Yu-Hua Hui, Scott W. Eastman, María José Lallena, Carmen Baquero, Carlos Marugán, Michele Dowless, Stephen R. Wasserman, Kenneth Weichert, Anna Pustilnik, Danalyn Manglicmot, Karen Froning, Ann M. Mc Nulty, Stephen Antonysamy, Avnish Kapoor, Li Fan, Chris Ficklin, Huimin Bian, Sufang Yao, Shaoling Jin, Bomie Han, Wayne Blosser, Xi Lin, Robert D. Van Horn, Li-Chun Chio, Philip W. Iversen, Yue Webster, Farhana F. Merzoug, Stephen H. Parsons, Jian Du, Xueqian Gong
LY3295668 chemical characterization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::459c3119cab021ba3189b2c2e7d96d2e
https://doi.org/10.1158/2159-8290.22533034.v1
https://doi.org/10.1158/2159-8290.22533034.v1
Autor:
Sean G. Buchanan, James R. Henry, Robert M. Campbell, Christoph Reinhard, Gregory D. Plowman, David A. Barda, Xiang S. Ye, Hui-Rong Qian, Shaoyou Chu, Thompson Doman, Matthew Z. Dieter, Yu-Hua Hui, Scott W. Eastman, María José Lallena, Carmen Baquero, Carlos Marugán, Michele Dowless, Stephen R. Wasserman, Kenneth Weichert, Anna Pustilnik, Danalyn Manglicmot, Karen Froning, Ann M. Mc Nulty, Stephen Antonysamy, Avnish Kapoor, Li Fan, Chris Ficklin, Huimin Bian, Sufang Yao, Shaoling Jin, Bomie Han, Wayne Blosser, Xi Lin, Robert D. Van Horn, Li-Chun Chio, Philip W. Iversen, Yue Webster, Farhana F. Merzoug, Stephen H. Parsons, Jian Du, Xueqian Gong
shRNA suppressor screening data for H446 and MDA-MB-468 cells (tabs 1, 2) and RNA expression level associations with LY3295668 Abs IC50 values from 493 cancer cell lines (tab 3).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f7062b69c7f18848d7e882885812c96
https://doi.org/10.1158/2159-8290.22533025.v1
https://doi.org/10.1158/2159-8290.22533025.v1
Autor:
Sean G. Buchanan, James R. Henry, Robert M. Campbell, Christoph Reinhard, Gregory D. Plowman, David A. Barda, Xiang S. Ye, Hui-Rong Qian, Shaoyou Chu, Thompson Doman, Matthew Z. Dieter, Yu-Hua Hui, Scott W. Eastman, María José Lallena, Carmen Baquero, Carlos Marugán, Michele Dowless, Stephen R. Wasserman, Kenneth Weichert, Anna Pustilnik, Danalyn Manglicmot, Karen Froning, Ann M. Mc Nulty, Stephen Antonysamy, Avnish Kapoor, Li Fan, Chris Ficklin, Huimin Bian, Sufang Yao, Shaoling Jin, Bomie Han, Wayne Blosser, Xi Lin, Robert D. Van Horn, Li-Chun Chio, Philip W. Iversen, Yue Webster, Farhana F. Merzoug, Stephen H. Parsons, Jian Du, Xueqian Gong
Supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071e82c7fa2f25274a31dc41f9817c55
https://doi.org/10.1158/2159-8290.22533037
https://doi.org/10.1158/2159-8290.22533037
Autor:
Hertzel C. Gerstein, Shun-Fu Lee, Guillaume Paré, M. Angelyn Bethel, Helen M. Colhoun, Anastasia Hoover, Mark Lakshmanan, Yanzhu Lin, Valentino Pirro, Hui-Rong Qian, Giacomo Ruotolo, Lars Ryden, Jonathan M. Wilson, Kevin L. Duffin
OBJECTIVE The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This article expores the relationship of selected biomarkers to both dulagluti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2640ca757c8cf50993017da4bd7b9737
https://doi.org/10.2337/figshare.22120097
https://doi.org/10.2337/figshare.22120097
Autor:
Katherine R. Tuttle, Jonathan Matthew Wilson, Yanzhu Lin, Hui-Rong Qian, Federica Genovese, Morten Asser Karsdal, Kevin L. Duffin, Fady T Botros
Publikováno v:
American Journal of Nephrology.
Introduction: In the AWARD-7 study in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, once-weekly dulaglutide slowed the decline in estimated glomerular filtration rate (eGFR) and decreased the urine albumin/creatinine ra
Autor:
VALENTINA PIRRO, GUILLAUME PARE, SHUN FU LEE, HELEN M. COLHOUN, YANZHU LIN, JONATHAN M. WILSON, HUI-RONG QIAN, ANASTASIA HOOVER, KEVIN L. DUFFIN, HERTZEL C. GERSTEIN
Publikováno v:
Diabetes. 71
Dulaglutide (DU) reduced the risk of CV outcomes compared with placebo (PL) in the REWIND trial (NCT01394952) , with a MACE-3 (major adverse CV events) hazard ratio of 0.88 over 5.4 years. Participants were ≥50 years of age with T2D, A1C ≤9.5%, B
Autor:
JONATHAN M. WILSON, GUILLAUME PARE, SHUN FU LEE, HELEN M. COLHOUN, HUI-RONG QIAN, VALENTINA PIRRO, ANASTASIA HOOVER, MARK LAKSHMANAN, GIACOMO RUOTOLO, KEVIN L. DUFFIN, HERTZEL C. GERSTEIN
Publikováno v:
Diabetes. 71
In the REWIND trial, dulaglutide (DU) reduced the risk of CV outcomes compared with placebo (PL) (Major Adverse Cardiovascular Event [MACE]-3 hazard ratio 0.88) . This post hoc analysis studied circulating protein biomarkers associated with CV events